Orally administrable opioid formulations having extended duratio

Details Orally administrable opioid formulations having extended duratio Orally administrable opioid formulations having extended duratio

1995-07-27

1999-10-19

Spear, James M.

Drug, bio-affecting and body treating compositions

Preparations characterized by special physical form

Capsules

424457, 424458, 424460, 424462, 424461, 424484, 424489, 424491, 424494, 424496, 424497, 424498, 5147723, 514781, 514782, A61K 916, A61K 948

Patent

active

059685514

ABSTRACT:
Sustained release oral solid dosage forms of opioid analgesics are provided as multiparticulate systems which are bioavailable and which provide effective blood levels of the opioid analgesic for at least about 24 hours. A unit dose of the opioid analgesic contains a plurality of substrates including the opioid analgesic in sustained release form. The substrates have a diameter from about 0.1 mm to about 3 mm.

REFERENCES:
patent: 3634584 (1972-01-01), Poole
patent: 3845770 (1974-11-01), Theeuwes et al.
patent: 3870790 (1975-03-01), Lowey et al.
patent: 3916899 (1975-11-01), Theeuwes et al.
patent: 4377568 (1983-03-01), Chopra
patent: 4385078 (1983-05-01), Onda et al.
patent: 4389393 (1983-06-01), Schor et al.
patent: 4483847 (1984-11-01), Augart
patent: 4520172 (1985-05-01), Lehmann et al.
patent: 4548990 (1985-10-01), Mueller et al.
patent: 4557925 (1985-12-01), Lindahl et al.
patent: 4600645 (1986-07-01), Ghebre-Sellassie et al.
patent: 4708874 (1987-11-01), De Haan et al.
patent: 4728513 (1988-03-01), Ventouras
patent: 4797410 (1989-01-01), El-Fakahany
patent: 4806337 (1989-02-01), Snipes et al.
patent: 4828836 (1989-05-01), Elger et al.
patent: 4834984 (1989-05-01), Goldie et al.
patent: 4834985 (1989-05-01), Elger et al.
patent: 4844907 (1989-07-01), Elger et al.
patent: 4844909 (1989-07-01), Goldie et al.
patent: 4861598 (1989-08-01), Oshlack
patent: 4970075 (1990-11-01), Oshlack
patent: 4983730 (1991-01-01), Domeshek et al.
patent: 4990341 (1991-02-01), Goldie et al.
patent: 5007790 (1991-04-01), Shell
patent: 5024842 (1991-06-01), Edgren et al.
patent: 5071646 (1991-12-01), Malkowska et al.
patent: 5122384 (1992-06-01), Paradissis et al.
patent: 5133974 (1992-07-01), Paradissis et al.
patent: 5169645 (1992-12-01), Shukla et al.
patent: 5178868 (1993-01-01), Malmqvist et al.
patent: 5202128 (1993-04-01), Morella et al.
patent: 5266331 (1993-11-01), Oshlack et al.
patent: 5273760 (1993-12-01), Oshlack et al.
patent: 5283065 (1994-02-01), Doyon et al.
patent: 5286493 (1994-02-01), Oshlack et al.
patent: 5321012 (1994-06-01), Mayer et al.
patent: 5330766 (1994-07-01), Morella et al.
patent: 5378474 (1995-01-01), Morella et al.
patent: 5411745 (1995-05-01), Oshlack et al.
patent: 5456923 (1995-10-01), Nakamichi et al.
patent: 5460826 (1995-10-01), Merrill et al.
patent: 5472712 (1995-12-01), Oshlack et al.
patent: 5500227 (1996-03-01), Oshlack et al.
patent: 5508042 (1996-04-01), Oshlack et al.
patent: 5520931 (1996-05-01), Persson et al.
patent: 5549912 (1996-08-01), Oshlack et al.
patent: 5580578 (1996-12-01), Oshlack et al.
patent: 5601842 (1997-02-01), Bartholomaeus
patent: 5614218 (1997-03-01), Olsson et al.
patent: 5672360 (1997-09-01), Sackler et al.
Maccarrone C. et al; Single Dose Pharmacokinetics of Kapanol.TM., a New Oral Sustained-Release Morphine Formulation; Clinical Drug Investigation 1994:7 (5): 262-274.
West RJ. Maccarrone C. Single dose pharmacokinetics of a new oral sustained release morphine formulation, Kapanol.TM. capsules. (Abstract 997) International Association for the Study of Pain, 7th World Congress on Pain. Paris, Aug. 22-27, 1993 (Data on file. Glaxo Australia, F.H. Faulding).
Gourlay GK, Plummer JL, Cherry DA, et al. A comparison of Kapanol.TM. (A new sustained release morphine formulation), MST Continus.RTM. and morphine solution in cancer patients: pharmacokinetic aspects. (Abstract 998) International Association for the Study of Pain, 7th World Congress on Pain. Paris, Aug. 22-27, 1993 (Data on file, Glaxo Australia, F.H. Faulding).
Cherry DA, Gourlay GK, Plummer JL, et al. A comparison of Kapanol.TM. (a new sustained release morphine formulation), MST Continus.RTM. and morphine solution in cancer patients: morphine metabolite profiles and renal function. (Abstract 999) International Association for the Study of Pain, 7th World Congress on Pain, Paris, Aug. 22-27, 1993.
Plummer JL, Cherry DA, Gourlay GK, et al. A comparison of Kapanol.TM. (a new sustained release morphine formulation) MST Continus.RTM. and morphine solution in cancer patients: pharmacodynamic aspects. (Abstract 1000) International Association for the Study of Pain, 7th World Congress on Pain, Paris, Aug. 22-27, 1993 (Data on file, Glaxo Australia, F.H. Faulding).
Toner G, Cramond T, Bishop J, et al. Randomized double blind, phase III crossover study of a new sustained-release oral morphine formulation, Kapanol.TM. capsules, (Abstract 1001) International Association for the Study of Pain, 7th World Congress on Pain, Paris, Aug. 22-27, 1993 (Data on file, Glaxo Australia, F.H. Faulding).
European Journal of Cancer; Once A Day (i.e. 24 Hourly) Kapanol.TM., A New Sustained Release Morphine Formulation, in the Treatment of Cancer Pain: Morphine Metabolite Profiles; Part A General Topics 1995;31 (S5) Suppl:S184 Abs 884, European Conference on Clinical Oncology and Cancer Nursing, Paris, Oct. 29-Nov. 2, 1995.
European Journal of Cancer; Once A Day (i.e. 24 Hourly) Kapanol.TM., A New Sustained Release Morphine Formulation, in The Treatment of Cancer Pain: Pharmacokinetic Aspects; Part A General Topics 1995:31 (S5) Suppl: S187 Abs 897 European Conference on Clinical Oncology and Cancer Nursing, Paris, Oct. 29-Nov. 2, 1995.
European Journal of Cancer; Kadian.TM./Kapanol.TM.--A Once Daily Morphine Formulation; Part A General Topics 1995;31 (S5) Suppl: S182 Abs 873 European Conference on Clinical Oncology and Cancer Nursing, Paris, Oct. 29-Nov. 2, 1995.
Gourlay et al., Proceeding of the 7th World Congress on Pain; A comparison of Kapanol (a New Sustained-Release Morphine Formulation), MST Continus, and Morphine Solution in Cancer Patients: Pharmacokinetic Aspects of Morphine and Morphine Metabolites Progress in Pain Research and Management vol. 2 pp. 631-643 1995.
Kaiko R.F.; Clinical Protocol and Role of Controlled Release Morphine in the Surgical Patient; Anesthesiology and Pain Management 1991 pp. 193-212.
MS Contin--Frequency of Daily Dosing (NDTI)--Jun., 1991-May, 1992.
MS Contin--Frequency of Daily Dosing--Jan.-Nov., 1990.
A protocol for a clinical study entitled "A Randomized, Double-Blind, Parallel-Group Study comparing the Efficacy and Safety of Kapanol.RTM. to Ms. Contin.RTM. in the Management of Patients with Moderate to Severe Cancer Pain" ("the Protocol"). The date of the Protocol is indicated as Feb. 10, 1992 and it bears CDD No. 14556. The sponsor of the study is indicated to be Faulding Pharmaceuticals, an Australian company.
R. West et al. World Congress on Pain Abstracts 997-1001, Aug. 26, 1993.
Advertisement: Roxanol SR., .COPYRGT.1988 Roxane Labs, Inc.
R. Kaiko and T. Hunt, Clin. Thera. vol. 13, No. 4, pp. 484-488, 1991.
S. Bloomfield, et al., Clin. Pharmacol. Ther., vol. 53, No. 4, pp. 469-478, 1993.
Advertisement: MS Contin.RTM. .COPYRGT.1986, 1987 The Purdue Frederick Company.
Advertisement: Roxanol SR, .COPYRGT.1988 Roxane Laboratories, Inc.
R. Kaiko and T. Hunt, "Comparison of the Pharmacokinetic Profiles of Two Oral Controlled-Release Morphine Formulations in Healthy Young Adults", Clin. Thera., vol. 13, No. 4, 1991.
R. West and C. Maccarrone, "Single Dose Pharmacokinetics of a New Oral Sustained-Release Morphine Formulation, Kapanol.RTM. Capsules", Abstracts--7th World Congress on Pain, Aug. 26, 1993, Abstracts 997-1001.
S. Bloomfield, et al., "Analgesic efficacy and potency of two oral controlled-release morphine preparations", Clin. Pharmacol. Ther., vol. 53, No. 4, pp. 469-478, .COPYRGT.1993.
Advertisement: MS Contin.RTM., .COPYRGT.1986, 1987, The Purdue Frederick Company.
Abraham Sunshine, et al., "Analgesic oral efficacy of tramadol hydrochloride in postoperative pain", Clin. Pharmacol. Ther., Jun. 1992, pp. 740-746.
E. Beubler, "Medikamentose Schmerztherapie: Kriterien, Moglichkeiten, Risken", Therapiewoche Osterreich, 7, 2 (1992), pp. 90-96, with English translation.
Geoffrey K. Gourlay, Ph.D., et al., "Influence of a high-fat meal on the absorption of morphine from oral solutions", Clin. Pharmacol. Ther., Oct. 1989, pp. 463-468.
Robert Kaiko, et al., "A Single-Dose Study Of The Effect Of Food Ingestion And Timing Of Dose Administration On The Pharmac

Affiliated with

Also associated with

Rating

Orally administrable opioid formulations having extended duratio does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Orally administrable opioid formulations having extended duratio, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Orally administrable opioid formulations having extended duratio will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2052390